The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of RxSight Inc (NASDAQ: RXST) was $12.31 for the day, down -2.30% from the previous closing price of $12.6. In other words, the price has decreased by -$2.30 from its previous closing price. On the day, 0.79 million shares were traded. RXST stock price reached its highest trading level at $12.88 during the session, while it also had its lowest trading level at $12.21.
Ratios:
Our analysis of RXST’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 11.44 and its Current Ratio is at 12.74. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
On July 10, 2025, Jefferies Downgraded its rating to Hold which previously was Buy but kept the price unchanged to $9.
Wells Fargo Downgraded its Overweight to Equal Weight on July 09, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 12 ’25 when Fountain Tamara sold 7,000 shares for $25.71 per share. The transaction valued at 180,002 led to the insider holds 24,793 shares of the business.
TAMARA R FOUNTAIN bought 7,000 shares of RXST for $180,002 on Mar 12 ’25. On Jan 22 ’25, another insider, Maniar Shweta, who serves as the Director of the company, sold 3,519 shares for $30.87 each. As a result, the insider received 108,618 and left with 7,383 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXST now has a Market Capitalization of 506145856 and an Enterprise Value of 290194848. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.56 while its Price-to-Book (P/B) ratio in mrq is 1.83. Its current Enterprise Value per Revenue stands at 2.042 whereas that against EBITDA is -6.82.
Stock Price History:
The Beta on a monthly basis for RXST is 1.10, which has changed by -0.6256684 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, RXST has reached a high of $38.64, while it has fallen to a 52-week low of $6.32. The 50-Day Moving Average of the stock is 22.80%, while the 200-Day Moving Average is calculated to be -1.67%.
Shares Statistics:
RXST traded an average of 780.76K shares per day over the past three months and 751060 shares per day over the past ten days. A total of 41.08M shares are outstanding, with a floating share count of 38.58M. Insiders hold about 6.16% of the company’s shares, while institutions hold 80.70% stake in the company. Shares short for RXST as of 1764288000 were 4440350 with a Short Ratio of 5.69, compared to 1761868800 on 3841484. Therefore, it implies a Short% of Shares Outstanding of 4440350 and a Short% of Float of 11.3299996.
Earnings Estimates
The market rating for RxSight Inc (RXST) is a result of the insights provided by 5.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.04 and low estimates of -$0.36.
Analysts are recommending an EPS of between -$0.3 and -$1.09 for the fiscal current year, implying an average EPS of -$0.47. EPS for the following year is -$0.49, with 5.0 analysts recommending between -$0.15 and -$1.13.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 8 analysts. It ranges from a high estimate of $28.62M to a low estimate of $26.52M. As of. The current estimate, RxSight Inc’s year-ago sales were $40.21MFor the next quarter, 8 analysts are estimating revenue of $30.89M. There is a high estimate of $33.26M for the next quarter, whereas the lowest estimate is $29.1M.
A total of 10 analysts have provided revenue estimates for RXST’s current fiscal year. The highest revenue estimate was $130.45M, while the lowest revenue estimate was $127.58M, resulting in an average revenue estimate of $129.25M. In the same quarter a year ago, actual revenue was $139.93MBased on 10 analysts’ estimates, the company’s revenue will be $134.67M in the next fiscal year. The high estimate is $142.1M and the low estimate is $130.3M.
